Reducing sitting time and increasing daily activity during cancer treatment
Official title: Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Run by Mälardalen University · NCT06719206 · Data updated 2026-11-12
This project will try a digital self-management program plus physiotherapist support to help people with breast, prostate, or colorectal cancer who are starting neo- or adjuvant treatment sit less and feel better during and after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | Mälardalen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Uppsala and 1 other locations) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2030 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT06719206 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with breast, prostate, or colorectal cancer who are planned for or recently started neo- or adjuvant treatment at participating hospitals in Uppsala or Västerås, who can walk independently and use digital tools, are the intended participants.
✕Probably not a fit
Patients with dementia, severe psychiatric disease, severe vision or communication impairments, inability to walk independently, or those recently treated for another cancer are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter randomized controlled study tests a digital self-management program developed with patients to reduce sedentary behavior during ongoing neo- or adjuvant treatment for breast, prostate, or colorectal cancer. Participants use existing goal-setting technology and receive physiotherapist support to choose activities that replace time spent sitting. The trial measures objectively recorded sedentary time, patient-reported well-being, and includes health-economic and climate-benefit analyses. Recruitment takes place at hospitals in Uppsala and Västerås, Sweden with short- and long-term follow-up.
Why it matters
Potential benefit: If effective, the intervention could help patients spend less time sitting during treatment, improve short-term well-being, and lower long-term risks such as treatment-related cardiovascular complications.
How similar studies have gone: Previous smaller trials and pilot studies suggest digital coaching and physiotherapist-supported programs can reduce sedentary time and improve quality of life in cancer patients, but large randomized multicenter evidence is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden. Exclusion Criteria: * Individuals diagnosed with dementia. * Individuals diagnosed with severe psychiatric disease. * Individuals with severe loss of vision, or communicative ability. * Individuals who cannot walk independently indoors with or without a walking aid. * Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.
Where it's running
-
Akademiska sjukhuset
Uppsala, Sweden Recruiting -
Västmanlands sjukhus
Västerås, Sweden Recruiting
Study contacts
- Principal investigator: Petra von Heideken Wågert, Professor — Mälardalen University
- Study coordinator: Petra von Heideken Wågert, Professor
- Email: petra.heideken.wagert@mdu.se
- Phone: +46 (0)21-10 3188
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
-
HER2 FPBMC therapy for metastatic breast and prostate cancer
This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response
This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.